Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shanghai AoHua Endoscope Raises $117 Million in IPO; Trades 71% Higher

publication date: Nov 15, 2021

Shanghai AoHua Endoscope completed a $117 million IPO on the Shanghai Star Exchange and rose 71% higher in its first trading session, bringing its market capitalization to over $800 million. Formed in 1994, AoHua develops and sells electronic endoscopic equipment and surgical consumables, making products for  gastroenterology, respiratory medicine, otolaryngology, gynecology, and emergency medicine uses. The company's stated goal is to become the world's leading provider of endoscope technology. More details....

Stock Symbol: (SHA: 688212)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China